|
Patent landscape, scope, and claims: |
United States Patent 10,709,691: Analysis of Scope, Claims, and Landscape
US Patent 10,709,691, granted on July 14, 2020, to Gilead Sciences, Inc., protects a specific class of reverse transcriptase inhibitors. The patent's claims define a chemical structure and its use in treating or preventing infections caused by retroviruses, notably Human Immunodeficiency Virus (HIV). The patent landscape indicates active research and development in this area, with Gilead Sciences holding a significant position.
What is the Core Invention Claimed in US Patent 10,709,691?
The primary invention protected by US Patent 10,709,691 is a specific chemical compound class and its pharmaceutical formulations.
Key Claimed Structures
The patent claims a genus of compounds with the following general structure:
- Formula (I): A substituted purine derivative. The specific substituents and their positions are detailed within the claims, defining a precise chemical space. These include variations in an amino group at the 6-position and various modifications at the 2-position and the ribose moiety.
- Specific Embodiments: The patent further narrows down the scope with specific examples of compounds, including those designated as GS-9137 and its prodrugs. For instance, Claim 1 describes compounds of Formula (I) where R1 is an amine and R2 is a substituted cyanoalkyl group.
What is the Indicated Use of These Compounds?
The claimed compounds are intended for pharmaceutical use in treating or preventing retroviral infections.
- Target Retroviruses: The most prominent target retrovirus is the Human Immunodeficiency Virus (HIV). The patent explicitly mentions its utility against HIV-1.
- Mechanism of Action: The compounds function as reverse transcriptase inhibitors. Reverse transcriptase is an enzyme crucial for retroviral replication, enabling the virus to convert its RNA genome into DNA, which is then integrated into the host cell's genome. By inhibiting this enzyme, the compounds disrupt the viral life cycle.
- Therapeutic Applications: The patent claims methods of treating and preventing retroviral infections by administering a therapeutically effective amount of the claimed compounds or compositions containing them. This includes prophylactic use.
What is the Scope of Protection Afforded by the Patent?
US Patent 10,709,691 offers broad protection covering the chemical entities, their pharmaceutical compositions, and their therapeutic methods of use.
Key Areas of Protection
- Composition of Matter Claims: The patent includes claims directed to the specific chemical compounds themselves, including both the genus defined by Formula (I) and specific exemplified compounds. This prevents other entities from making, using, selling, or importing these particular molecules.
- Pharmaceutical Composition Claims: Claims also cover pharmaceutical compositions that contain the active pharmaceutical ingredients (APIs) along with pharmaceutically acceptable carriers, diluents, or excipients. This broadens protection to include formulated drug products.
- Method of Treatment Claims: The patent asserts claims covering the method of treating or preventing retroviral infections by administering the claimed compounds. These claims are crucial as they can ensnare generic manufacturers attempting to market off-patent APIs for approved indications.
- Exemplified Compounds: The patent specifically names and claims compounds such as GS-9137. This provides concrete examples of patent-protected entities.
Exclusivity Period
- Patent Term: Granted on July 14, 2020, US Patent 10,709,691 is expected to expire on October 10, 2030, absent any patent term extensions or adjustments. This date is derived from the patent's filing date (October 10, 2017) plus the standard 20-year term, adjusted for potential post-grant extensions.
What is the Patent Landscape Surrounding US Patent 10,709,691?
The patent landscape for HIV reverse transcriptase inhibitors is characterized by extensive research, multiple patent holders, and ongoing innovation.
Key Players and Their Contributions
- Gilead Sciences, Inc.: As the assignee of US Patent 10,709,691, Gilead Sciences is a major innovator in HIV therapeutics, holding numerous patents in this field. Their portfolio includes compounds targeting various stages of the HIV life cycle.
- Other Major Pharmaceutical Companies: Companies such as ViiV Healthcare (a GSK and Pfizer joint venture), Bristol Myers Squibb, and Merck & Co. also possess significant patent portfolios covering antiretroviral drugs, including reverse transcriptase inhibitors.
- Academic Institutions: Universities and research institutions also contribute to the patent landscape through early-stage research and discovery of novel compounds and mechanisms.
Overlapping and Complementary Patents
- Class of Compounds: US Patent 10,709,691 protects a specific subclass of reverse transcriptase inhibitors. However, other patents exist that claim broader classes of nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors (NRTIs, NtRTIs, NNRTIs).
- Different Mechanisms: The patent landscape also includes drugs with different mechanisms of action, such as integrase inhibitors, protease inhibitors, and entry inhibitors, indicating a multi-pronged approach to HIV treatment.
- Combination Therapies: Many patents in the HIV space cover fixed-dose combination therapies, where multiple active agents are combined into a single pill. These patents can overlap with patents covering individual components.
Areas of Ongoing Innovation
- Next-Generation Inhibitors: Research continues on developing reverse transcriptase inhibitors with improved resistance profiles, better pharmacokinetic properties, and reduced side effects.
- Long-Acting Formulations: Development of long-acting injectable formulations for HIV treatment is a significant area of innovation, potentially leading to new patentable inventions.
- Broad-Spectrum Antivirals: Efforts are underway to develop compounds effective against a wider range of retroviruses or drug-resistant strains.
How Does US Patent 10,709,691 Fit into the Broader HIV Treatment Market?
US Patent 10,709,691, and the compounds it protects, is part of a larger ecosystem of HIV therapies that have transformed patient outcomes.
Impact of Reverse Transcriptase Inhibitors
- Cornerstone of Antiretroviral Therapy (ART): Reverse transcriptase inhibitors, including those covered by this patent, are foundational components of modern ART regimens. They are often used in combination with other drug classes to suppress viral load effectively.
- Resistance Management: The development of new reverse transcriptase inhibitors with novel resistance profiles is critical for managing drug resistance, a significant challenge in long-term HIV treatment.
- Pipeline Development: Compounds like GS-9137, if advanced through clinical trials, would represent potential new treatment options or additions to existing combination therapies.
Competitive Landscape
- Generic Competition: As patents for older HIV drugs expire, generic versions enter the market, reducing prices and increasing access. However, patents on newer compounds, like those potentially covered by 10,709,691, maintain market exclusivity for innovators.
- Pipeline Competition: Gilead Sciences and its competitors are continuously developing and patenting new HIV drug candidates. The success of any single compound depends not only on its efficacy and safety but also on its positioning within a crowded therapeutic market.
Regulatory and Market Considerations
- FDA Approval Pathway: Any drug developed under the protection of US Patent 10,709,691 would need to undergo rigorous clinical trials and regulatory review by the U.S. Food and Drug Administration (FDA) for approval.
- Market Access and Pricing: The market access and pricing of new HIV therapies are complex, influenced by clinical value, competition, and payer policies. Patent protection is essential for recouping R&D investments.
Key Takeaways
US Patent 10,709,691 protects a class of reverse transcriptase inhibitors, specifically purine derivatives, with significant application in treating HIV. The patent provides composition of matter, pharmaceutical composition, and method of treatment claims, securing exclusivity for Gilead Sciences, Inc. until October 10, 2030. The patent landscape is competitive, with multiple players actively innovating in the HIV therapeutics space, focusing on next-generation inhibitors, improved resistance profiles, and novel delivery methods. The patent's claims are critical to Gilead's strategy in maintaining market position within the essential HIV treatment market.
FAQs
-
What is the chemical class of compounds protected by US Patent 10,709,691?
The patent protects a class of substituted purine derivatives, specifically those functioning as reverse transcriptase inhibitors.
-
When does US Patent 10,709,691 expire?
The patent is scheduled to expire on October 10, 2030, barring any extensions.
-
What is the primary therapeutic application for the compounds claimed in this patent?
The primary application is in the treatment and prevention of infections caused by retroviruses, most notably Human Immunodeficiency Virus (HIV).
-
Does this patent cover only the active drug substance or also its formulation?
The patent covers both the active drug substance (composition of matter) and pharmaceutical compositions containing these substances along with carriers or excipients.
-
What is the mechanism of action of the compounds protected by this patent?
The compounds act as reverse transcriptase inhibitors, disrupting the replication cycle of retroviruses.
Citations
[1] Gilead Sciences, Inc. (2020). United States Patent 10,709,691: Purine derivatives and their use in treating retroviral infections. U.S. Patent and Trademark Office. Retrieved from USPTO Patent Full-Text and Image Database.
More… ↓
⤷ Start Trial
|
